CN111346158A - Application of traditional Chinese medicine composition in treating gastrointestinal dysfunction - Google Patents
Application of traditional Chinese medicine composition in treating gastrointestinal dysfunction Download PDFInfo
- Publication number
- CN111346158A CN111346158A CN202010335842.8A CN202010335842A CN111346158A CN 111346158 A CN111346158 A CN 111346158A CN 202010335842 A CN202010335842 A CN 202010335842A CN 111346158 A CN111346158 A CN 111346158A
- Authority
- CN
- China
- Prior art keywords
- parts
- gastrointestinal dysfunction
- rats
- group
- gastrointestinal
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003814 drug Substances 0.000 title claims abstract description 64
- 239000000203 mixture Substances 0.000 title claims abstract description 31
- 230000007160 gastrointestinal dysfunction Effects 0.000 title claims description 36
- 241001116389 Aloe Species 0.000 claims abstract description 24
- 235000011399 aloe vera Nutrition 0.000 claims abstract description 24
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 claims abstract description 17
- 235000003140 Panax quinquefolius Nutrition 0.000 claims abstract description 17
- 235000008434 ginseng Nutrition 0.000 claims abstract description 17
- 241000132012 Atractylodes Species 0.000 claims abstract description 16
- 108010010803 Gelatin Proteins 0.000 claims abstract description 16
- 229920000159 gelatin Polymers 0.000 claims abstract description 16
- 239000008273 gelatin Substances 0.000 claims abstract description 16
- 235000019322 gelatine Nutrition 0.000 claims abstract description 16
- 235000011852 gelatine desserts Nutrition 0.000 claims abstract description 16
- 244000183685 Citrus aurantium Species 0.000 claims abstract description 14
- 235000007716 Citrus aurantium Nutrition 0.000 claims abstract description 14
- 244000037364 Cinnamomum aromaticum Species 0.000 claims abstract description 11
- 235000014489 Cinnamomum aromaticum Nutrition 0.000 claims abstract description 11
- 239000002775 capsule Substances 0.000 claims description 40
- 241000208340 Araliaceae Species 0.000 claims description 16
- 238000002360 preparation method Methods 0.000 claims description 16
- 230000007661 gastrointestinal function Effects 0.000 claims description 12
- 238000001356 surgical procedure Methods 0.000 claims description 12
- 235000017784 Mespilus germanica Nutrition 0.000 claims description 11
- 244000182216 Mimusops elengi Species 0.000 claims description 11
- 235000000560 Mimusops elengi Nutrition 0.000 claims description 11
- 235000007837 Vangueria infausta Nutrition 0.000 claims description 11
- 241001289529 Fallopia multiflora Species 0.000 claims description 10
- 238000000034 method Methods 0.000 claims description 10
- 238000011084 recovery Methods 0.000 claims description 9
- 239000003826 tablet Substances 0.000 claims description 9
- 208000010643 digestive system disease Diseases 0.000 claims description 8
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 7
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 7
- 201000002528 pancreatic cancer Diseases 0.000 claims description 7
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 7
- 239000008187 granular material Substances 0.000 claims description 6
- 230000003187 abdominal effect Effects 0.000 claims description 5
- 108010052008 colla corii asini Proteins 0.000 claims description 5
- 235000005911 diet Nutrition 0.000 claims description 5
- 208000008469 Peptic Ulcer Diseases 0.000 claims description 4
- 201000010099 disease Diseases 0.000 claims description 4
- 239000002552 dosage form Substances 0.000 claims description 4
- 208000011906 peptic ulcer disease Diseases 0.000 claims description 4
- 210000000582 semen Anatomy 0.000 claims description 4
- 206010033645 Pancreatitis Diseases 0.000 claims description 3
- 208000021302 gastroesophageal reflux disease Diseases 0.000 claims description 3
- 230000001737 promoting effect Effects 0.000 claims description 3
- 208000035473 Communicable disease Diseases 0.000 claims description 2
- 208000007882 Gastritis Diseases 0.000 claims description 2
- 208000018522 Gastrointestinal disease Diseases 0.000 claims description 2
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 2
- 208000007107 Stomach Ulcer Diseases 0.000 claims description 2
- 238000012084 abdominal surgery Methods 0.000 claims description 2
- 201000011510 cancer Diseases 0.000 claims description 2
- 238000002512 chemotherapy Methods 0.000 claims description 2
- 201000001352 cholecystitis Diseases 0.000 claims description 2
- 206010009887 colitis Diseases 0.000 claims description 2
- 206010012601 diabetes mellitus Diseases 0.000 claims description 2
- 230000000378 dietary effect Effects 0.000 claims description 2
- 208000000718 duodenal ulcer Diseases 0.000 claims description 2
- 201000006549 dyspepsia Diseases 0.000 claims description 2
- 206010017758 gastric cancer Diseases 0.000 claims description 2
- 201000005917 gastric ulcer Diseases 0.000 claims description 2
- 208000018685 gastrointestinal system disease Diseases 0.000 claims description 2
- 208000024348 heart neoplasm Diseases 0.000 claims description 2
- 208000024557 hepatobiliary disease Diseases 0.000 claims description 2
- 208000015181 infectious disease Diseases 0.000 claims description 2
- 239000006187 pill Substances 0.000 claims description 2
- 238000001959 radiotherapy Methods 0.000 claims description 2
- 201000011549 stomach cancer Diseases 0.000 claims description 2
- 239000002671 adjuvant Substances 0.000 claims 1
- 239000010135 fructus aurantii immaturus Substances 0.000 claims 1
- 241000700159 Rattus Species 0.000 abstract description 91
- 210000000813 small intestine Anatomy 0.000 abstract description 12
- 238000002474 experimental method Methods 0.000 abstract description 6
- 244000241838 Lycium barbarum Species 0.000 abstract description 5
- 235000015459 Lycium barbarum Nutrition 0.000 abstract description 5
- 235000015468 Lycium chinense Nutrition 0.000 abstract description 5
- 235000013399 edible fruits Nutrition 0.000 abstract description 5
- 230000005176 gastrointestinal motility Effects 0.000 abstract description 4
- 230000030136 gastric emptying Effects 0.000 abstract description 3
- 230000000144 pharmacologic effect Effects 0.000 abstract description 3
- 229940126680 traditional chinese medicines Drugs 0.000 abstract description 3
- 240000001341 Reynoutria japonica Species 0.000 abstract description 2
- 235000018167 Reynoutria japonica Nutrition 0.000 abstract description 2
- 244000131316 Panax pseudoginseng Species 0.000 abstract 1
- 230000001766 physiological effect Effects 0.000 abstract 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 24
- 239000000706 filtrate Substances 0.000 description 24
- 230000013872 defecation Effects 0.000 description 21
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 21
- 229940079593 drug Drugs 0.000 description 19
- LVRVABPNVHYXRT-BQWXUCBYSA-N 52906-92-0 Chemical compound C([C@H](N)C(=O)N[C@H](C(=O)N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(O)=O)C(C)C)C1=CC=CC=C1 LVRVABPNVHYXRT-BQWXUCBYSA-N 0.000 description 18
- 102400000921 Gastrin Human genes 0.000 description 18
- 108010052343 Gastrins Proteins 0.000 description 18
- 101800002372 Motilin Proteins 0.000 description 18
- 102400001357 Motilin Human genes 0.000 description 18
- AOXOCDRNSPFDPE-UKEONUMOSA-N chembl413654 Chemical compound C([C@H](C(=O)NCC(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@H](CCSC)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](C)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H]1N(CCC1)C(=O)CNC(=O)[C@@H](N)CCC(O)=O)C1=CC=C(O)C=C1 AOXOCDRNSPFDPE-UKEONUMOSA-N 0.000 description 18
- 230000000052 comparative effect Effects 0.000 description 17
- 210000002381 plasma Anatomy 0.000 description 17
- 238000001914 filtration Methods 0.000 description 16
- 230000002496 gastric effect Effects 0.000 description 16
- 210000000496 pancreas Anatomy 0.000 description 13
- 238000002156 mixing Methods 0.000 description 12
- 230000000638 stimulation Effects 0.000 description 12
- 230000037406 food intake Effects 0.000 description 10
- 235000012631 food intake Nutrition 0.000 description 10
- 210000002784 stomach Anatomy 0.000 description 10
- YPELFRMCRYSPKZ-UHFFFAOYSA-N 4-amino-5-chloro-2-ethoxy-N-({4-[(4-fluorophenyl)methyl]morpholin-2-yl}methyl)benzamide Chemical compound CCOC1=CC(N)=C(Cl)C=C1C(=O)NCC1OCCN(CC=2C=CC(F)=CC=2)C1 YPELFRMCRYSPKZ-UHFFFAOYSA-N 0.000 description 9
- 229960004085 mosapride Drugs 0.000 description 9
- 239000000843 powder Substances 0.000 description 9
- 241001465754 Metazoa Species 0.000 description 7
- 210000001198 duodenum Anatomy 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 230000000968 intestinal effect Effects 0.000 description 7
- 210000001630 jejunum Anatomy 0.000 description 7
- 238000010992 reflux Methods 0.000 description 7
- 239000003629 gastrointestinal hormone Substances 0.000 description 6
- 210000001035 gastrointestinal tract Anatomy 0.000 description 6
- 235000016709 nutrition Nutrition 0.000 description 6
- 230000035764 nutrition Effects 0.000 description 6
- 230000002980 postoperative effect Effects 0.000 description 6
- 201000011603 cardia cancer Diseases 0.000 description 5
- 210000003238 esophagus Anatomy 0.000 description 5
- 238000013110 gastrectomy Methods 0.000 description 5
- 210000000936 intestine Anatomy 0.000 description 5
- 238000002791 soaking Methods 0.000 description 5
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 4
- 206010010774 Constipation Diseases 0.000 description 4
- 239000004375 Dextrin Substances 0.000 description 4
- 229920001353 Dextrin Polymers 0.000 description 4
- 210000001015 abdomen Anatomy 0.000 description 4
- 230000003872 anastomosis Effects 0.000 description 4
- 210000001367 artery Anatomy 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 238000005520 cutting process Methods 0.000 description 4
- 235000019425 dextrin Nutrition 0.000 description 4
- 238000001035 drying Methods 0.000 description 4
- 239000008141 laxative Substances 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 210000004923 pancreatic tissue Anatomy 0.000 description 4
- 238000010298 pulverizing process Methods 0.000 description 4
- 238000007873 sieving Methods 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 206010002091 Anaesthesia Diseases 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 210000000683 abdominal cavity Anatomy 0.000 description 3
- 230000037005 anaesthesia Effects 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- 230000036772 blood pressure Effects 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 230000037213 diet Effects 0.000 description 3
- 208000035475 disorder Diseases 0.000 description 3
- 210000001105 femoral artery Anatomy 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 230000002475 laxative effect Effects 0.000 description 3
- 230000003902 lesion Effects 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 230000004936 stimulating effect Effects 0.000 description 3
- 230000009182 swimming Effects 0.000 description 3
- 208000004998 Abdominal Pain Diseases 0.000 description 2
- 206010000060 Abdominal distension Diseases 0.000 description 2
- 206010000087 Abdominal pain upper Diseases 0.000 description 2
- 241000218236 Cannabis Species 0.000 description 2
- 206010012735 Diarrhoea Diseases 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 208000002193 Pain Diseases 0.000 description 2
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 2
- 206010047700 Vomiting Diseases 0.000 description 2
- 208000022531 anorexia Diseases 0.000 description 2
- 210000000013 bile duct Anatomy 0.000 description 2
- 210000002318 cardia Anatomy 0.000 description 2
- 210000001953 common bile duct Anatomy 0.000 description 2
- 230000002354 daily effect Effects 0.000 description 2
- 206010061428 decreased appetite Diseases 0.000 description 2
- 230000000994 depressogenic effect Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 230000035487 diastolic blood pressure Effects 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 239000005457 ice water Substances 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 230000006996 mental state Effects 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 230000036407 pain Effects 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 230000000391 smoking effect Effects 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 230000035488 systolic blood pressure Effects 0.000 description 2
- 239000003053 toxin Substances 0.000 description 2
- 231100000765 toxin Toxicity 0.000 description 2
- 230000008673 vomiting Effects 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- WEEMDRWIKYCTQM-UHFFFAOYSA-N 2,6-dimethoxybenzenecarbothioamide Chemical compound COC1=CC=CC(OC)=C1C(N)=S WEEMDRWIKYCTQM-UHFFFAOYSA-N 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 208000012639 Balance disease Diseases 0.000 description 1
- 206010006895 Cachexia Diseases 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- 206010013954 Dysphoria Diseases 0.000 description 1
- 238000008157 ELISA kit Methods 0.000 description 1
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010021518 Impaired gastric emptying Diseases 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- 206010024642 Listless Diseases 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 239000004107 Penicillin G sodium Substances 0.000 description 1
- 208000035965 Postoperative Complications Diseases 0.000 description 1
- 244000299790 Rheum rhabarbarum Species 0.000 description 1
- 235000009411 Rheum rhabarbarum Nutrition 0.000 description 1
- 241000555745 Sciuridae Species 0.000 description 1
- 208000033041 Somatoform disorder gastrointestinal Diseases 0.000 description 1
- 208000026062 Tissue disease Diseases 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 1
- 238000011047 acute toxicity test Methods 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 210000002255 anal canal Anatomy 0.000 description 1
- 210000003484 anatomy Anatomy 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 210000000436 anus Anatomy 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 206010003549 asthenia Diseases 0.000 description 1
- 208000006766 bile reflux Diseases 0.000 description 1
- 210000004534 cecum Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- RNFNDJAIBTYOQL-UHFFFAOYSA-N chloral hydrate Chemical compound OC(O)C(Cl)(Cl)Cl RNFNDJAIBTYOQL-UHFFFAOYSA-N 0.000 description 1
- 229960002327 chloral hydrate Drugs 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 230000007012 clinical effect Effects 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 230000006837 decompression Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 210000002249 digestive system Anatomy 0.000 description 1
- 208000024829 digestive system symptom Diseases 0.000 description 1
- 238000007908 dry granulation Methods 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 208000026500 emaciation Diseases 0.000 description 1
- 238000001839 endoscopy Methods 0.000 description 1
- 235000020774 essential nutrients Nutrition 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 239000008098 formaldehyde solution Substances 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 238000002682 general surgery Methods 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 210000001564 haversian system Anatomy 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- ATADHKWKHYVBTJ-UHFFFAOYSA-N hydron;4-[1-hydroxy-2-(methylamino)ethyl]benzene-1,2-diol;chloride Chemical compound Cl.CNCC(O)C1=CC=C(O)C(O)=C1 ATADHKWKHYVBTJ-UHFFFAOYSA-N 0.000 description 1
- 230000009610 hypersensitivity Effects 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000008991 intestinal motility Effects 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 238000002386 leaching Methods 0.000 description 1
- 210000003041 ligament Anatomy 0.000 description 1
- 208000017971 listlessness Diseases 0.000 description 1
- 231100001252 long-term toxicity Toxicity 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000002932 luster Substances 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 210000001758 mesenteric vein Anatomy 0.000 description 1
- 210000000713 mesentery Anatomy 0.000 description 1
- 230000004089 microcirculation Effects 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 230000036651 mood Effects 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 208000015706 neuroendocrine disease Diseases 0.000 description 1
- 235000021590 normal diet Nutrition 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 235000020660 omega-3 fatty acid Nutrition 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000007310 pathophysiology Effects 0.000 description 1
- 235000019369 penicillin G sodium Nutrition 0.000 description 1
- 229940056360 penicillin g Drugs 0.000 description 1
- 230000008855 peristalsis Effects 0.000 description 1
- 210000004303 peritoneum Anatomy 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 210000003240 portal vein Anatomy 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 210000001187 pylorus Anatomy 0.000 description 1
- 238000003127 radioimmunoassay Methods 0.000 description 1
- 230000002040 relaxant effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000033764 rhythmic process Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 229960002385 streptomycin sulfate Drugs 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 210000003384 transverse colon Anatomy 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 238000004506 ultrasonic cleaning Methods 0.000 description 1
- 210000001186 vagus nerve Anatomy 0.000 description 1
- 230000002227 vasoactive effect Effects 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 238000009423 ventilation Methods 0.000 description 1
- 230000009278 visceral effect Effects 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 208000016261 weight loss Diseases 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/70—Polygonaceae (Buckwheat family), e.g. spineflower or dock
- A61K36/704—Polygonum, e.g. knotweed
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/36—Skin; Hair; Nails; Sebaceous glands; Cerumen; Epidermis; Epithelial cells; Keratinocytes; Langerhans cells; Ectodermal cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
- A61K36/258—Panax (ginseng)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/284—Atractylodes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/482—Cassia, e.g. golden shower tree
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/75—Rutaceae (Rue family)
- A61K36/752—Citrus, e.g. lime, orange or lemon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/81—Solanaceae (Potato family), e.g. tobacco, nightshade, tomato, belladonna, capsicum or jimsonweed
- A61K36/815—Lycium (desert-thorn)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/886—Aloeaceae (Aloe family), e.g. aloe vera
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation or decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/53—Liquid-solid separation, e.g. centrifugation, sedimentation or crystallization
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Biotechnology (AREA)
- Epidemiology (AREA)
- Medical Informatics (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Botany (AREA)
- Alternative & Traditional Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cell Biology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Nutrition Science (AREA)
- Zoology (AREA)
- Virology (AREA)
- Dermatology (AREA)
- Developmental Biology & Embryology (AREA)
- Biomedical Technology (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention belongs to the technical field of traditional Chinese medicines, and particularly relates to a traditional Chinese medicine composition and application thereof. The invention relates to a new application of a traditional Chinese medicine composition developed on the basis of a patent CN100453105C, wherein the traditional Chinese medicine composition is mainly prepared from immature bitter orange, largehead atractylodes rhizome, ginseng, barbary wolfberry fruit, donkey-hide gelatin, tuber fleeceflower root, cassia seed and aloe. The pharmacological experiment of the invention shows that: the Chinese medicinal composition can obviously improve the physiological activity of rats and accelerate the gastric emptying and small intestine propulsion rate of the rats; obviously improve the MTL and GAS content in the plasma of the rat, reduce the SS, CCK and VIP content and promote the gastrointestinal motility.
Description
Technical Field
The invention relates to a new application of a traditional Chinese medicine composition, in particular to an application of the traditional Chinese medicine composition in preparing a medicine for treating or improving gastrointestinal dysfunction, and belongs to the technical field of traditional Chinese medicines.
Background
Gastrointestinal dysfunction, also known as gastrointestinal neurosis, is a general term for a group of gastrointestinal syndromes, and refers to a group of digestive system syndromes which have digestive system symptoms such as abdominal distension, abdominal pain, diarrhea, constipation and the like, are mainly characterized by gastrointestinal motility dysfunction and visceral hypersensitivity, and have no organic lesions found by biochemical, imaging, endoscopic examination or the like, or cannot explain the symptoms by organic diseases. There are many causes of gastrointestinal dysfunction, such as irregular diet, pathological causes, or psychological factors.
The autonomous movement of the gastrointestinal tract is one of the most important functions of the digestive tract, gastrointestinal dysfunction is a common complication after general surgery, and the main causes comprise surgical factors such as surgical anesthesia, trauma, bed rest in the convalescent period, postoperative fasting, electrolyte balance disorder, abdominal inflammation, mechanical stimulation and the like, and also comprise neuroendocrine disorder, gastrointestinal electrophysiological disorder, change of anatomical structure, inflammatory reaction, gastrointestinal microcirculation disorder and the like. The main pathophysiology manifestations of the drug are delayed gastric emptying, slowed intestinal propulsion, and disordered gastrointestinal coordinated movement rhythm, and the clinical manifestations are nausea, vomiting, abdominal distension, abdominal pain, difficult defecation or diarrhea, and the like, and no effective treatment means and drugs exist at present (refer to Zhouyitong, Xiaoyi, and the like, discussion of diagnosis and treatment problem of functional gastric emptying disorder after Whipple operation [ J ]. China general surgical journal, 2002,11 (17): 671-.
A large number of researches prove that mental states play a certain role in the pathogenesis of gastrointestinal functional diseases, the movement and secretion of the stomach even can stop under the terror and disappointed mood, and the intestinal peristalsis is in a suppression state under the depression and the gray heart. Conversely, gastrointestinal dysfunction can lead to further development and progression of depression.
The gastrointestinal dysfunction has high morbidity, long medical history, repeated attack and complex etiology, and the medical science does not determine long-term effective treatment medicines and methods, thereby seriously affecting the life quality of patients.
Chinese patent CN100453105C discloses a composition with functions of relaxing bowels, expelling toxin, losing weight and reducing fat and a preparation method thereof. The composition is prepared from eight traditional Chinese medicines of polygonum multiflorum, aloe, cassia seed, medlar, donkey-hide gelatin, ginseng, bighead atractylodes rhizome and immature bitter orange, and has a good treatment effect on constipation caused by toxin accumulation and yin fluid deficiency. Related products are already on the market and have the product name 'hou hui cathartic capsule'.
Disclosure of Invention
The invention relates to a new application of a traditional Chinese medicine composition developed on the basis of the Chinese patent of invention CN100453105C in treating or improving gastrointestinal dysfunction.
The invention aims to provide application of a traditional Chinese medicine composition mainly prepared from polygonum multiflorum, cassia seed, aloe, medlar, donkey-hide gelatin, ginseng, immature bitter orange and bighead atractylodes rhizome in preparing a medicine for treating or improving gastrointestinal dysfunction and application of the traditional Chinese medicine composition in preparing a medicine for improving gastrointestinal function or promoting gastrointestinal function recovery.
The traditional Chinese medicine composition is prepared from the following components:
80-120 parts of polygonum multiflorum, 100 parts of cassia seed, 120 parts of aloe and 160 parts of aloe
50-80 parts of medlar, 40-80 parts of donkey-hide gelatin, 20-50 parts of ginseng
80-120 parts of immature bitter orange and 30-50 parts of bighead atractylodes rhizome;
preferably, the traditional Chinese medicine composition is prepared from the following components:
120 parts of polygonum multiflorum, 140 parts of cassia seed and 160 parts of aloe
75 parts by weight of medlar, 75 parts by weight of donkey-hide gelatin, 50 parts by weight of ginseng
120 parts of immature bitter orange and 50 parts of bighead atractylodes rhizome.
The gastrointestinal dysfunction of the present invention refers to gastrointestinal dysfunction caused by abdominal surgery.
Preferably, the abdominal operation includes, but is not limited to, one of gastrointestinal disease operation, hepatobiliary disease operation, infectious disease operation, and gynecological disease operation.
The gastrointestinal dysfunction of the present invention may be gastrointestinal dysfunction caused by digestive system diseases and diabetes.
Preferably, the digestive system disease includes but is not limited to one of dyspepsia, gastritis, peptic ulcer, colitis, gastroesophageal reflux, cholecystitis, pancreatitis, and gastric cancer;
further preferably, the peptic ulcer includes but is not limited to one of gastric ulcer and duodenal ulcer.
The gastrointestinal dysfunction of the present invention may also be gastrointestinal dysfunction caused by radiotherapy, chemotherapy and/or surgery for malignant tumors.
Preferably, the gastrointestinal dysfunction is gastrointestinal dysfunction caused by pancreatic cancer or cardiac cancer surgery.
The gastrointestinal dysfunction of the invention also comprises gastrointestinal dysfunction caused by dietary factors, mental factors and pharmaceutical factors.
The second purpose of the invention is to provide a traditional Chinese medicine preparation containing the traditional Chinese medicine composition, and the traditional Chinese medicine composition can be prepared into clinically acceptable dosage forms directly through conventional procedures or after medically acceptable auxiliary materials are added;
preferably, the clinically acceptable dosage form comprises one or more of capsules, tablets, granules, pills and powder.
Further preferably, the capsule is a aloe cathartic capsule.
The invention also provides a preparation method of the aloe cathartic capsule, which comprises the following steps:
(1) pulverizing colla Corii Asini into fine powder, and sieving with 80 mesh sieve;
(2) reflux-extracting Ginseng radix, Polygoni Multiflori radix, semen Cassiae and Aloe with 60% ethanol for 2 times, 10 times for the first time and 8 times for the second time, each time for 2 hr, filtering, and mixing filtrates to obtain filtrate I;
(3) decocting the wolfberry fruit, the bighead atractylodes rhizome and the immature bitter orange twice by adding water, adding 8 times of water for the first time, soaking for 1 hour, decocting for 1.5 hours, filtering, adding 6 times of water for the second time, decocting for 1.5 hours, filtering, combining the filtrates, concentrating to obtain clear paste with the relative density of 1.10-1.20 (80 ℃), placing at room temperature, stirring, adding ethanol to ensure that the purity reaches 60 percent (20 ℃), refrigerating, standing for more than 24 hours, and filtering to obtain filtrate II for later use;
(4) and (3) mixing the filtrate I obtained in the step (2) and the filtrate II obtained in the step (3), concentrating to obtain thick paste with the relative density of 1.30-1.35(70 ℃), drying, crushing, adding the donkey-hide gelatin fine powder prepared in the step (1) and a proper amount of dextrin, uniformly mixing, performing dry granulation, and filling into capsules to obtain the donkey-hide gelatin capsule.
Compared with the prior art, the invention has the following remarkable technical effects:
animal pharmacological tests and clinical tests show that the traditional Chinese medicine composition is an effective prescription for treating gastrointestinal dysfunction, improving gastrointestinal function and promoting gastrointestinal function recovery. Animal experiments show that the Chinese medicinal composition can remarkably accelerate the gastric emptying and small intestine propelling speeds of rats, promote the release and secretion of MTL and GAS of the rats, and reduce the content of inhibitory hormones such as VIP, SS, CCK and the like, so that the gastrointestinal motility function is improved.
Clinical effect observation shows that the aloe-laxative capsule has positive promotion effect on improving the intestinal gastrointestinal hormone level of a patient after pancreatic cancer operation, and further promotes the recovery of the gastrointestinal function of the patient; the aloe laxative capsule can increase the times of air exhaust and defecation of patients after the total gastrectomy of cardia cancer and promote the evacuation of intestinal tracts, thereby reducing the reflux of upper digestive tract liquid, relieving the reflux related complications after the total gastrectomy and improving the quality of life.
DETAILED DESCRIPTION OF EMBODIMENT (S) OF INVENTION
First, the detailed description of the invention
The following examples are provided to further disclose the present invention, and it should be noted that these examples are only preferred embodiments of the present invention, and do not limit the scope of the present invention as claimed.
EXAMPLE 1 preparation of Hui Tongbiang Capsule
The prescription is as follows:
120g of polygonum multiflorum, 140g of cassia seed, 160g of aloe
75g of medlar, 75g of donkey-hide gelatin, 50g of ginseng
Immature bitter orange 120g white atractylodes rhizome 50g
The preparation method comprises the following steps:
taking the donkey-hide gelatin in the prescription amount, crushing into fine powder, and sieving with a 80-mesh sieve for later use; reflux-extracting Ginseng radix, Polygoni Multiflori radix, semen Cassiae and Aloe with 60% ethanol for 2 times, 10 times for the first time and 8 times for the second time, each time for 2 hr, filtering, and mixing filtrates to obtain filtrate I; decocting wolfberry fruit, bighead atractylodes rhizome and immature bitter orange according to the prescription amount twice by adding water, adding 8 times of water for the first time, soaking for 1 hour, decocting for 1.5 hours, filtering, adding 6 times of water for the second time, decocting for 1.5 hours, filtering, combining filtrates, concentrating to obtain clear paste with the relative density of 1.10-1.20 (80 ℃), standing at room temperature, stirring, adding ethanol until the purity reaches 60% (20 ℃), refrigerating and standing for more than 24 hours, and filtering to obtain a filtrate II; mixing the filtrate I and the filtrate II, concentrating to obtain soft extract with relative density of 1.30-1.35(70 deg.C), drying, pulverizing, adding colla Corii Asini fine powder and appropriate amount of dextrin, mixing, dry granulating, and making into capsule with 1000 granules.
EXAMPLE 2 Capsule preparation
The prescription is as follows:
120g of polygonum multiflorum, 100g of cassia seed, 120g of aloe
50g of medlar, 80g of donkey-hide gelatin, 20g of ginseng
80g of immature bitter orange and 30g of bighead atractylodes rhizome;
the preparation method comprises the following steps: the preparation method is the same as that of example 1.
EXAMPLE 3 Capsule preparation
The prescription is as follows:
polygonum multiflorum 80g cassia seed 150g aloe 160g
80g of medlar, 40g of donkey-hide gelatin, 50g of ginseng
120g of immature bitter orange and 50g of bighead atractylodes rhizome;
the preparation method of the traditional Chinese medicine composition comprises the following steps: the preparation method is the same as that of example 1.
Comparative example 1 preparation of capsules
The prescription is as follows:
120g of fleece-flower root, 140g of fructus cannabis and 160g of rhubarb
75g of medlar, 75g of donkey-hide gelatin, 50g of ginseng
120g of immature bitter orange and 50g of bighead atractylodes rhizome;
the preparation method comprises the following steps:
taking the donkey-hide gelatin in the prescription amount, crushing into fine powder, and sieving with a 80-mesh sieve for later use; reflux-extracting Ginseng radix, Polygoni Multiflori radix, fructus Cannabis and radix et rhizoma Rhei with 60% ethanol for 2 times, 10 times for the first time and 8 times for the second time for 2 hr each time, filtering respectively, and mixing filtrates to obtain filtrate I; decocting wolfberry fruit, bighead atractylodes rhizome and immature bitter orange according to the prescription amount twice by adding water, adding 8 times of water for the first time, soaking for 1 hour, decocting for 1.5 hours, filtering, adding 6 times of water for the second time, decocting for 1.5 hours, filtering, combining filtrates, concentrating to obtain clear paste with the relative density of 1.10-1.20 (80 ℃), standing at room temperature, stirring, adding ethanol until the purity reaches 60% (20 ℃), refrigerating and standing for more than 24 hours, and filtering to obtain a filtrate II; mixing the filtrate I and the filtrate II, concentrating to obtain soft extract with relative density of 1.30-1.35(70 deg.C), drying, pulverizing, adding colla Corii Asini fine powder and appropriate amount of dextrin, mixing, dry granulating, and making into capsule with 1000 granules.
Comparative example 2
The prescription is as follows:
120g of polygonum multiflorum, 140g of cassia seed, 160g of aloe
75g of medlar, 75g of donkey-hide gelatin, 50g of ginseng
Costustoot 120g and bighead atractylodes rhizome 50 g;
the preparation method comprises the following steps:
taking the donkey-hide gelatin in the prescription amount, crushing into fine powder, and sieving with a 80-mesh sieve for later use; reflux-extracting Ginseng radix, Polygoni Multiflori radix, semen Cassiae and Aloe with 60% ethanol for 2 times, 10 times for the first time and 8 times for the second time, each time for 2 hr, filtering, and mixing filtrates to obtain filtrate I; decocting wolfberry fruit, bighead atractylodes rhizome and costustoot according to the prescription amount in water twice, adding 8 times of water for the first time, soaking for 1 hour, decocting for 1.5 hours, filtering, adding 6 times of water for the second time, decocting for 1.5 hours, filtering, combining filtrates, concentrating to obtain clear paste with the relative density of 1.10-1.20 (80 ℃), standing at room temperature, stirring, adding ethanol until the purity reaches 60% (20 ℃), refrigerating and standing for more than 24 hours, and filtering to obtain a filtrate II; mixing the filtrate I and the filtrate II, concentrating to obtain soft extract with relative density of 1.30-1.35(70 deg.C), drying, pulverizing, adding colla Corii Asini fine powder and appropriate amount of dextrin, mixing, dry granulating, and making into capsule with 1000 granules.
Second, zoology experiment
In order to verify the efficacy of the traditional Chinese medicine composition in treating gastrointestinal dysfunction or improving gastrointestinal function, the inventor carries out the following experimental study, only a part of experimental models are taken as an example for illustration, and pharmacological experimental study is also carried out on gastrointestinal dysfunction caused by other reasons described in the specification.
The inventor explains that the following experimental studies are carried out on the basis of the safety of the drug proved by acute toxicity tests and long-term toxicity tests, and the administration dose in the experimental studies is within a safe dose range.
(I) the influence of the traditional Chinese medicine composition on the gastrointestinal dysfunction of rats after abdominal operations.
1 Material
1.1 animals:
SD rat, weight 180 ~ 220g, experimental animal license number: SYXK (lu) 20180008, provided by lumnan pharmaceutical group ltd, was acclimatized for one week prior to the experiment.
1.2 drugs, reagents
1.2.1 medicaments
Capsules obtained in examples 1 and 2 of the present invention
Comparative examples capsules obtained in comparative examples 1 and 2
Positive drug mosapride citrate tablet
1.2.3 dosage for rats
Example 1 capsule: 0.378g/kg (high dose), 0.189g/kg (medium dose), 0.0945g/kg (low dose);
example 2 capsules: 0.189 g/kg;
comparative example 1 capsule: 0.189 g/kg;
mosapride citrate tablets: 1.35 mg/kg.
2. Animal surgery, grouping and administration
Taking 70 rats, after fasting and no water supply for 24 hours, carrying out injection anesthesia by 10% chloral hydrate, opening the abdomen, carrying out transverse incision on the colon 2cm below the cecum without cutting, carrying out in-situ suturing and closing the abdomen, wherein the two parts are 2cm away from each other and have the caliber of about 2 mm; after surgery for 24h, the patients were randomly divided into a surgery model group, a positive drug group, three dose groups of example 1 (high, medium and low), an example 2 group and a comparative example 1 group.
Another 10 rats were selected as a sham-operated group, and the abdominal cavity was opened and closed immediately.
Feeding the rats in a single cage after operation, and injecting penicillin G sodium and streptomycin sulfate subcutaneously for 3 days continuously; after operation, the patient is fasted and not forbidden to drink within 48h, and the patient is gavaged with 20% glucose 2 times daily at intervals of 8h, and the patient is gavaged with 20ml/kg feed paste on day 3 and is free to eat on day 4.
After 24h, the sham operation group and the operation model group are perfused with normal saline according to the volume of 10ml/kg, and the other groups are perfused with corresponding medicines.
Dosing was started 24h after surgery for 10 days.
3. Detecting the index
3.1 postoperative defecation and movement
After the administration for 2 hours on the 3 rd day after operation, each rat is filled with 20ml/kg of gastric lavage feed paste, the first defecation time is observed and recorded, the first defecation time is checked for 1 time every 1 hour, and the time is counted for 10 hours when more than 10 hours of continuous defecation time are not found. Feces in 6h of each group of rats are collected, the wet weight is weighed, and the mental state, the activity condition and the like of the rats are observed.
3.2 postoperative food intake and intestinal transit Rate
3.2.1 adding 50g of feed in the morning on the 3 rd, 6 th and 9 th days before and after the operation respectively, weighing the rest feed at the same time the next day, weighing body mass and calculating the food intake of 24 h.
3.2.2 after the last administration 30min on the 10 th day after operation, each group of rats was gavaged with a mixed solution of 10% acacia gum and 5% activated carbon at 20ml/kg, after 45min, blood was taken from femoral artery, the rats were sacrificed, a median incision was made along the abdomen, the whole stomach and intestine was taken out, the mesentery was separated, the total length of the small intestine (from pylorus to ileocecal part) and the distance of carbon powder propulsion were measured, and the small intestine propulsion index was calculated.
3.3 MTL, GAS content in plasma
After 75min from the last administration, blood was taken from the femoral artery of each rat to prepare plasma, and the MTL and GAS levels in the plasma were measured using an ELISA kit according to the instructions.
4. Results and conclusions
4.1 postoperative defecation and mobility of rats
The skin and hair of the rats in the sham operation group are better in luster, active in posture, regular in excrement and hard in quality and are not adhered to each other; the rest rats showed different degrees of listlessness, slow movement, and scanty stool after operation.
Compared with a sham operation group, the first defecation time of the rats in the rest groups on the third day after operation is obviously prolonged, the defecation amount in 6h is obviously reduced, and the difference is very obvious (P is less than 0.01); compared with the operation model group, the first defecation time of the positive medicine group and the group of the embodiment 1 (high and medium dosage) is obviously shortened, the defecation amount is obviously increased within 6h, and the obvious difference is achieved (P is less than 0.05, and P is less than 0.01); compared with the positive drug, the first defecation time of the rats in the high-dose group is obviously shortened, the defecation amount is obviously increased within 6h, and the rats have obvious difference (P is less than 0.01) in the example 1 (middle and low dose) group and the rats in the example 2 (P is more than 0.05)
TABLE 1 defecation amount at defecation time level for each group of rats
Note: in contrast to the sham-operated group,@P＜0.05，*P＜0.01；
in contrast to the set of surgical models,△P＜0.05，#P＜0.01；
compared with the positive medicine group,&P＜0.05，￥P＜0.01。
4.2 variation in body Mass of rats
The constitution of rats in each group before operation has no difference (P is more than 0.05);
on the 3 rd day after the operation, compared with a sham operation group, the body mass of rats in other groups is obviously reduced, and the body mass of the rats has extremely obvious difference (P is less than 0.01) and is slowly increased; after treatment, compared with a model group, except the group of the comparative example 1, the body mass of rats in the other administration groups is obviously increased, and the obvious difference P is less than 0.05; compared with the positive drug, the body mass of the rats in the high-dose group in the example 1 is obviously increased and has obvious difference (P is less than 0.01), and the rats in the medium-dose and low-dose groups in the example 1 and the example 2 have no difference (P is more than 0.05)
TABLE 2 Mass changes of rats in each group: (
n＝10)
Note: in contrast to the sham-operated group,@P＜0.05，*P＜0.01；
in contrast to the set of surgical models,△P＜0.05，#P＜0.01；
compared with the positive medicine group,&P＜0.05，￥P＜0.01。
4.3 rat food intake of 24h
Before operation, the food intake of rats in each group for 24 hours is not different (P is more than 0.05);
on the 3 rd day after the operation, compared with a sham operation group, the food intake of rats in other groups for 24h is obviously reduced, and the difference is very obvious (P is less than 0.01); after treatment, compared with the model group, the food intake of rats in the other administration groups except the comparative example 1 group is obviously increased, and the difference is obvious (P is less than 0.05); compared with the positive drug, the food intake of the rats in the high-dose group is obviously increased and has obvious difference (P is less than 0.01) in the example 1, and the rats in the medium-dose and low-dose groups have no difference (P is more than 0.05) in the example 2
TABLE 3 rat groups with 24h food intake: (
n＝10)
Note: in contrast to the sham-operated group,@P＜0.05，*P＜0.01；
and surgeryThe comparison of the model groups is carried out,△P＜0.05，#P＜0.01；
compared with the positive medicine group,&P＜0.05，￥P＜0.01。
4.4 Small intestine Propulsion index in rats
Compared with the sham operation group, the treated rats have no difference in small intestine propulsion index (P is more than 0.05) except for the model group, the example 2 group and the comparative example 1 group;
TABLE 4 Small intestine Propulsion index of rats in each group
Note: in contrast to the sham-operated group,@P＜0.05，*P＜0.01；
in contrast to the set of surgical models,△P＜0.05，#P＜0.01；
compared with the positive medicine group,&P＜0.05，￥P＜0.01。
4.5 MTL and GAS content in rat plasma
Compared with a sham operation group, the contents of MTL and GAS in the plasma of the model group are obviously reduced, and the model group has extremely significant difference (P is less than 0.01); after the treatment is finished, compared with the model group, the rats in each treatment group have the significantly increased MTL and GAS contents in the plasma of the other rats except the comparative example 1, and have significant difference (P is less than 0.05); compared with the positive medicine group, the high-dose group in the example 1 has obvious difference (P is less than 0.05)
TABLE 5 plasma MTL and GAS of various groups of rats: (A)
n＝10)
Note: in contrast to the sham-operated group,@P＜0.05，*P＜0.01；
in contrast to the set of surgical models,△P＜0.05，#P＜0.01；
compared with the positive medicine group,&P＜0.05，￥P＜0.01。
(II) the traditional Chinese medicine composition has the influence on the gastrointestinal movement of rats with liver depression type gastrointestinal dysfunction.
1 Material
1.1 animals:
SD level rat, weight 180 ~ 220g, experimental animal license number: SYXK (lu) 20180008, provided by lumnan pharmaceutical group ltd, was acclimatized for one week prior to the experiment.
1.2 drugs, reagents
1.2.1 medicaments
Capsules obtained in examples 1 and 3 of the present invention
Comparative example 2 the obtained capsule
The positive medicine of mosapride citrate tablet.
1.2.3 dosage for rats
Example 1 capsule: 0.378g/kg (high dose), 0.189g/kg (medium dose), 0.0945g/kg (low dose);
example 3 capsules: 0.189 g/kg;
comparative example 2 capsule: 0.189 g/kg;
mosapride citrate tablets: 1.35 mg/kg.
2. Grouping, modeling and administration
80 rats were randomly divided into a blank group, a model group, a positive drug group, three dose groups of example 1 (high, medium, and low), an example 3 group, and a comparative example 2 group, each group consisting of 10 rats.
Except the blank group, the other groups are molded by adopting various methods of external stimulation and drug stimulation, and the molded rats are molded by alternately stimulating (different stimulation methods are carried out on the rats every day) for 15 days continuously.
The stimulation method comprises tail-clamping stimulation (2 tail-clamping stimulation modes are adopted randomly, one mode is that a clamp with cotton cloth clamps each rat for 5min to enable the rats to mutually support due to pain, the other mode is that 10 rats are randomly drawn for tail-clamping stimulation, and the other rats are stimulated by the stimulation of the 10 rats), tail suspension (the heads of the rats are hung downwards 30cm away from the ground to struggle and keep the view of escaping and the state of failing to escape for 5min, the rat is kept in a suspended state all the time), day and night inversion (the rat is kept in a day and night inversion state for 24h), sc adrenaline hydrochloride (0.8mg/kg), rat cage inclination stimulation (the rat cage is obliquely placed to keep an inclination angle of 30 degrees with the ground, the rats in the cage are in an obliquely-clamped state for 24h), water deprivation is carried out for 12h, ice water swimming (the prepared crushed ice is placed into a water bucket, adding water to 50cm, putting the rat into water, struggling and swimming for 4min until it does not float on the water surface, and ultrasonic stimulating (placing the rat beside an ultrasonic cleaning instrument, adjusting frequency to 60Hz, making the rat in dysphoria state, and stopping stimulating after 15 min).
From day 16, the blank and model groups were gavaged with saline and the remaining groups were gavaged with the corresponding drugs. The administration was continued for 7 days.
3. Detection of
3.1 gastric residual rate and intestinal transit rate test: the rats in each group are fasted for no water supply one night before the gastric lavage administration is finished, 2ml (containing 5% carbon powder) of gastric lavage solid nutrition paste is added after 30min of the last gastric lavage administration, after 30min, the rats are dissected, the whole stomach is taken out, after the conventional treatment, the total weight of the stomach is weighed, the residue in the stomach is cleaned, after the surface moisture is sucked up after the cleaning, the net weight of the stomach is weighed, and the residual quantity of the solid nutrition paste in the stomach is calculated.
And taking out the complete small intestine section, soaking the small intestine section into 4% formaldehyde solution, measuring the whole length of the intestine section and the moving length of the solid nutrient paste in the intestine section after the intestine section is solidified and hardened, and calculating the small intestine propulsion rate.
3.2 rat gastro-plasma gut hormone changes: after each group of animals is administered for 30min for the last time, the femoral artery is bled, and the MTL and GAS contents are determined after plasma separation.
4. Results and conclusions
4.1 gastric residual Rate and intestinal Pushing Rate
After treatment, compared with a blank control group, the gastric residual rate of a model group rat is obviously increased, the small intestine propulsion rate is obviously reduced, and the model group rat has obvious difference (P is less than 0.05), and the positive medicine group and the example 1 (high, medium and low dose) group have no difference (P is more than 0.05); compared with the model group, the residual rate of the stomach of the rats in other treatment groups is obviously reduced, the small intestine propulsion rate is obviously improved, and the significant difference is realized (P is less than 0.05).
TABLE 6 gastric residual rate and intestinal propulsion rate of each group of rats
Note: in contrast to the blank group,@P＜0.05，*P＜0.01；
in contrast to the model set,△P＜0.05，#P＜0.01；
compared with the positive medicine group,&P＜0.05，￥P＜0.01。
4.2 gastrointestinal hormone content in rat plasma
After treatment, compared with a blank control group, the contents of MTL and GAS in the plasma of the model group are obviously reduced, and the contents are very different (P is less than 0.01); compared with the model group, the rats in each treatment group have significantly increased MTL and GAS contents in the plasma of the other rats except the comparative example 2 group, and have significant difference (P < 0.05); compared with the positive drug group, the group of example 1 (high and medium dose) was indistinguishable (P > 0.05).
TABLE 7 MTL, GAS in the plasma of various groups of rats: (
n＝10)
Note: in contrast to the blank group,@P＜0.05，*P＜0.01；
in contrast to the model set,△P＜0.05，#P＜0.01；
compared with the positive medicine group,&P＜0.05，￥P＜0.01。
(III) the influence of the traditional Chinese medicine composition on the gastrointestinal function of depressed rats.
1 Material
1.1 animals:
SD level rat, weight 180 ~ 220g, experimental animal license number: SYXK (lu) 20180008, provided by lumnan pharmaceutical group ltd, was acclimatized for one week prior to the experiment.
1.2 drugs, reagents
1.2.1 medicaments
Capsules obtained in examples 1 and 2 of the present invention
Comparative example 1 Capsule
The positive medicine of mosapride citrate tablet.
1.2.3 dosage for rats
Example 1 capsule: 0.378g/kg (high dose), 0.189g/kg (medium dose), 0.0945g/kg (low dose);
example 2 capsules: 0.189 g/kg;
comparative example 1 capsule: 0.189 g/kg;
mosapride citrate tablets: 1.35 mg/kg.
2. Modeling, grouping and administration
80 rats were randomly divided into a blank group, a model group, a positive drug group, three dose groups of example 1 (high, medium and low), and an example 2 group, and 10 rats in each group were selected as a comparative example 1 group.
Except for the blank group, the rest groups prepared depression models by combining chronic unpredictable mild stimulation and lone nutrition.
1 rat per cage was fed with the following 8 stress factors randomly given within 21 days: fasting for 24 hours without water supply; the food is not fasted for 24 hours under the condition of water deprivation; clamping tail for 1 min; swimming for 5min with ice water; noise for 5 min; performing restraint stimulation for 6 h; the wet padding and the squirrel cage are inclined for 24 hours; suspending for 5 min.
One stimulus was given daily, and each stimulus was used 2-3 times cumulatively, in a random order, making the rats unpredictable in the occurrence of the stimulus.
From 15d, the blank group and the model group are subjected to intragastric administration of physiological saline, and the other groups are subjected to intragastric administration of corresponding medicaments. The administration was continued for 7 days.
3. Detection of
Blood is taken from the canthus vein in the eye of the rat, plasma is separated, and the content of GAS, MTL, CCK, SS and VIP is determined.
4. Results and conclusions
After treatment, compared with a blank group of rats, the contents of SS, CCK and VIP in the plasma of the model group of rats are obviously increased, the contents of GAS and MTL are obviously reduced, and the significant difference is realized (P is less than 0.01); compared with the model group, the contents of SS, CCK and VIP in the plasma of rats in each treatment group are obviously reduced, the contents of GAS and MTL are obviously increased, and the significant difference is realized (P is less than 0.05 and P is less than 0.01).
TABLE 8 GAS, MTL, CCK, SS, VIP (VIP) in the plasma of various groups of rats
n＝10)
Note: in contrast to the blank group,@P＜0.05，*P＜0.01；
in contrast to the model set,△P＜0.05，#P＜0.01；
compared with the positive medicine group,&P＜0.05，￥P＜0.01。
in conclusion, the traditional Chinese medicine composition can obviously improve the contents of MTL and GAS in the blood plasma of depressed rats, reduce the contents of SS, CCK and VIP and promote gastrointestinal motility.
Third, clinical cases
(one time) the effect of the laxative capsules on gastrointestinal function of patients after pancreatic cancer surgery
1. Introduction of cases
Male, 73 years old, with persistent constipation one month before admission, manifested by anorexia, epigastric pain, emaciation, and upper abdominal pressure pain with lumps; there is no family history of pancreatic cancer, no pancreatitis, there is a history of smoking; the stomach-invigorating and digestion-promoting tablet and the anti-inflammatory treatment are taken before admission, and are not obviously improved. After admission, B-ultrasonic examination and MRI examination are carried out, pancreas puncture tissue disease examination shows that the maximum diameter of the lesion part of the pancreatic head is 5.2cm, the boundary is fuzzy, and the pancreatic cancer is diagnosed. The blood pressure is higher at present, and the blood pressure is moderate and high (the systolic pressure is 171mmHg, and the diastolic pressure is 103 mmHg).
2. Treatment of
After clinical pathological examination, the treatment of pancreaticoduodenectomy is performed according to the condition of a patient. The specific method comprises the following steps: adopting a Beger improvement method, dissociating duodenum and head of pancreas by a Kocher method, exposing pancreas through an approach of a gastrointestinal ligament, cutting off a neck of pancreas in front of a superior mesenteric vein and a portal vein, cutting a pancreas capsule along the inner side of an superior anterior artery of pancreas duodenum, dissecting an upper anterior artery and an upper posterior artery of pancreas duodenum, keeping the integrity of an artery arch of pancreas duodenum, completely excising pancreas head, keeping pancreas tissues 0.5-1.0 cm away from the inner side edge of the duodenum, completely stripping the pancreas tissues at the inner side of the pancreas after exposing a bile duct in pancreas in operation, keeping a thin layer of pancreas tissues between a common bile duct and duodenum and at the outer side of the common bile duct, ligating and cutting off a main pancreas duct at a joint of the bile duct, and intermittently suturing the pancreas tissues at the head end, and performing end-nested double-layer anastomosis of the far-end pancreas and the jejunum. Patient postoperative administration of early enteral immune tube-feeding support therapy: after 2 days of operation, 300ml of normal saline is fed through a nasal duodenum nutrient canal, a rey nutrient preparation (each 100ml contains 2.3g of arginine, 0.3g of omega-3 polyunsaturated fatty acid, proper amount of nucleotide, glutamine and the like, a plurality of vitamins and trace elements) is fed after the patient is confirmed to have no uncomfortable symptoms, then the dose on the 1 st day is 1/3-1/2 of the total dose, the dose on the 2 nd day is 2/3 of the total dose, and the dose on the 3 rd day is the total dose; the infusion speed is gradually increased from 30ml/h to 80-100 ml/h on day 1, and the treatment is continuously carried out for 1 week. The composition is administered orally to patients 1 week after operation, and is administered 3 times per day, 1 granule each time for 1 week
Collecting 5ml of early morning fasting venous blood of the patient at 1 week and 2 weeks before and after operation, respectively, and detecting the levels of serum gastrointestinal hormone Gastrin (GAS), Motilin (MTL) and vasoactive peptide (VIP) by radioimmunoassay, the results are shown in Table 9; the results of comparing the recovery time of gastrointestinal function before and after surgery including anal ventilation time, defecation time, and bowel sound recovery time are shown in table 10.
TABLE 9 comparison of gastrointestinal hormone levels before and after treatment
| GAS(μmol/l) | MTL(ng/l) | VIP(ng/l) | |
| Before operation | 58.72±7.23 | 153.52±25.82 | 68.47±17.33 |
| 1 week after operation | 74.68±6.77 | 240.18±24.27 | 53.75±16.57 |
| 2 weeks after surgery | 81.33±7.69 | 267.36±26.24 | 42.37±15.19 |
TABLE 10 comparison of gastrointestinal function recovery before and after treatment (Tian)
| Time of anus exhaust | Defecation time | Time to recovery from bowel sound | |
| Before operation | 2.58±0.73 | 2.63±0.81 | 2.49±0.82 |
| 1 week after operation | 2.25±1.03 | 2.13±1.07 | 1.86±1.05 |
| 2 weeks after surgery | 1.65±0.58 | 1.42±0.63 | 1.17±0.58 |
Early enteral nutrition can reduce the possibility of constipation after pancreatic cancer operation, but after the enteral nutrition is matched with the aloe cathartic capsule, the enteral nutrition has better effect, has positive promotion effect on improving the gastrointestinal hormone level in intestines, and further promotes the recovery of the gastrointestinal function of patients.
(II) the influence of the Hui Tongbi capsule on the complications of the patients with cardia cancer after total gastrectomy.
1. Introduction of cases
Female aged 81 years, before admission, manifested as food intake obstruction, vomiting after food intake, weight loss, epigastric pain, anorexia, asthenia, and dark stool. After the patient is admitted, ultrasonic endoscopy and CT examination are carried out, the maximum diameter of the lesion part is 6.5cm, the proportion of the cardia cancer leaching serosa reaches 90 percent, and the patient is diagnosed with the cardia cancer. The patients have a history of smoking, and the current blood pressure value is higher, the moderate hypertension (the systolic pressure is 173mmHg, the diastolic pressure is 102mmHg) is higher, and the patients have a history of severe esophageal reflux.
2. Treatment of
According to the condition of the patient, after radical total gastrectomy, esophagus jejunum anastomosis and Braun anastomosis treatment are adopted. The specific method comprises the following steps: the patient lies down, after disinfection and anesthesia, the abdomen is opened and the patient enters the abdominal cavity, the jejunum is cut off at a position 15cm below the ligamentum flexor, and the jejunum at the far end is dissociated and left for anastomosis. Then the ligamentum trigonum on the left side is cut off, the peritoneum below and in front of the diaphragmatic fissure is cut off, the left outer lobe of the liver is pulled to the right side by a large-size draw hook, the cardia part of the diaphragm and the esophageal fissure are exposed, the two sides and the front wall of the lower esophagus are separated, after vagus nerves on the two sides are cut off, the lower esophagus is stretched for about 5cm in the abdominal cavity, the front wall is transversely cut at a position, about 2cm above the tumor of the cardia part at the bottom of the stomach, the free distal jejunum upwards passes through the transverse colon and the stomach, the esophagus is anastomosed at the esophageal cut position with the esophagus, and the Braun which is close to 10cm is anastomosed at a position, 40-45 cm below the jejunum anastomotic stoma, of the jejunum output loop and the. After two groups of operations, gastrointestinal decompression is continued for 3 days, diet is forbidden, fluid diet can be taken only after anal canal is exhausted, semifluid is taken after about 8 days, and normal diet is taken after about 2 weeks. The conventional antibiotics are taken after operation to supplement essential nutrients such as protein and the like.
After 5 days after operation, the patient starts to take orally the mosapride 1 capsule with the combination of the initial aloe and the laxative after taking orally the mosapride for 3 days, and the bile reflux and the defecation times of the patient are respectively recorded. The statistical results are shown in table 1.
TABLE 11 comparison of postoperative complications before and after treatment of patients
This case shows that the combination increases the number of exsufflation and defecation times by comparing the single oral administration of mosapride with the combination of hui defaecation capsules for the treatment of cardia cancer postoperative reflux and defecation; meanwhile, the reflux times are reduced, and the reflux amount is reduced obviously. Therefore, the aloe bowel-relaxing capsule combined with the intestinal motility drug can increase the times of air exhaust and defecation and promote the emptying of the intestinal tract, thereby reducing the reflux of upper digestive tract liquid, relieving the reflux related complications after the total gastrectomy and improving the quality of life.
Claims (10)
1. A Chinese medicinal composition for treating or improving gastrointestinal dysfunction is prepared from Polygoni Multiflori radix, semen Cassiae, Aloe, fructus Lycii, colla Corii Asini, Ginseng radix, fructus Aurantii Immaturus, and Atractylodis rhizoma.
2. Use of the composition of claim 1 in the preparation of a medicament for improving or promoting recovery of gastrointestinal function.
3. The use of claim 1, wherein the gastrointestinal dysfunction is gastrointestinal dysfunction caused by abdominal surgery; preferably, the abdominal operation includes, but is not limited to, one of gastrointestinal disease operation, hepatobiliary disease operation, infectious disease operation, and gynecological disease operation.
4. The use according to claim 1, wherein the gastrointestinal dysfunction is gastrointestinal dysfunction caused by digestive diseases, diabetes.
5. The use of claim 4, wherein the digestive system disease includes, but is not limited to, one of dyspepsia, gastritis, peptic ulcer, colitis, gastroesophageal reflux, cholecystitis, pancreatitis, gastric cancer; preferably, the peptic ulcer includes but is not limited to one of gastric ulcer and duodenal ulcer.
6. The use of claim 1, wherein the gastrointestinal dysfunction is gastrointestinal dysfunction caused by radiation therapy, chemotherapy and/or surgery for a malignant tumor.
7. The use of claim 7, wherein the gastrointestinal dysfunction is gastrointestinal dysfunction induced by surgery for pancreatic cancer or cardiac cancer.
8. The use of claim 1, wherein the gastrointestinal dysfunction is gastrointestinal dysfunction caused by dietary factors, psychiatric factors, pharmaceutical factors.
9. The use of any one of claims 1-8, wherein the traditional Chinese medicine composition is prepared from the following components:
80-120 parts of polygonum multiflorum, 100 parts of cassia seed, 120 parts of aloe and 160 parts of aloe
50-80 parts of medlar, 40-80 parts of donkey-hide gelatin, 20-50 parts of ginseng
80-120 parts of immature bitter orange and 30-50 parts of bighead atractylodes rhizome;
preferably, the traditional Chinese medicine composition is prepared from the following components:
120 parts of polygonum multiflorum, 140 parts of cassia seed and 160 parts of aloe
75 parts by weight of medlar, 75 parts by weight of donkey-hide gelatin, 50 parts by weight of ginseng
120 parts of immature bitter orange and 50 parts of bighead atractylodes rhizome.
10. The use of claim 9, wherein the Chinese medicinal composition can be prepared into clinically acceptable dosage forms by conventional processes directly or after adding pharmaceutically acceptable adjuvants; preferably, the clinically acceptable dosage form is one or more of capsules, tablets, granules and pills; further preferably, the capsule is a aloe cathartic capsule.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010335842.8A CN111346158A (en) | 2020-04-25 | 2020-04-25 | Application of traditional Chinese medicine composition in treating gastrointestinal dysfunction |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010335842.8A CN111346158A (en) | 2020-04-25 | 2020-04-25 | Application of traditional Chinese medicine composition in treating gastrointestinal dysfunction |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN111346158A true CN111346158A (en) | 2020-06-30 |
Family
ID=71189635
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202010335842.8A Pending CN111346158A (en) | 2020-04-25 | 2020-04-25 | Application of traditional Chinese medicine composition in treating gastrointestinal dysfunction |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN111346158A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113117006A (en) * | 2021-03-20 | 2021-07-16 | 鲁南制药集团股份有限公司 | Application of traditional Chinese medicine composition in preparation of anti-skin-aging drugs or cosmetics |
| CN113332373A (en) * | 2021-07-14 | 2021-09-03 | 鲁南制药集团股份有限公司 | Application of aloe cathartic preparation in preparing medicine for treating vomiting |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1748765A (en) * | 2004-09-17 | 2006-03-22 | 鲁南制药集团股份有限公司 | Composition with catharsis and toxin expelling, fat reducing and weight reducing function and preparing method |
| CN109464570A (en) * | 2018-11-23 | 2019-03-15 | 鲁南制药集团股份有限公司 | A kind of head luxuriant growth Tongbian capsule preparation process |
-
2020
- 2020-04-25 CN CN202010335842.8A patent/CN111346158A/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1748765A (en) * | 2004-09-17 | 2006-03-22 | 鲁南制药集团股份有限公司 | Composition with catharsis and toxin expelling, fat reducing and weight reducing function and preparing method |
| CN109464570A (en) * | 2018-11-23 | 2019-03-15 | 鲁南制药集团股份有限公司 | A kind of head luxuriant growth Tongbian capsule preparation process |
Non-Patent Citations (1)
| Title |
|---|
| 李冰冰等: "首荟通便胶囊对慢传输型便秘模型大鼠肠道推进率和结肠黏液分泌的影响" * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113117006A (en) * | 2021-03-20 | 2021-07-16 | 鲁南制药集团股份有限公司 | Application of traditional Chinese medicine composition in preparation of anti-skin-aging drugs or cosmetics |
| CN113332373A (en) * | 2021-07-14 | 2021-09-03 | 鲁南制药集团股份有限公司 | Application of aloe cathartic preparation in preparing medicine for treating vomiting |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN109674958B (en) | Traditional Chinese medicine composition with effect of reducing uric acid and preparation method and application thereof | |
| CN111346158A (en) | Application of traditional Chinese medicine composition in treating gastrointestinal dysfunction | |
| CN114949143A (en) | Traditional Chinese medicine composition with effect of treating infantile anorexia and preparation method and application thereof | |
| CN104435990A (en) | Traditional Chinese medicinal composition for promoting recovery of gastrointestinal function after abdominal operation and preparation method of traditional Chinese medicinal composition | |
| CN111388587A (en) | Traditional Chinese medicine composition for preparing medicine for treating functional dyspepsia | |
| CN117481342A (en) | Composition for reducing side effects of drug vomiting as well as preparation method and application thereof | |
| KR101136285B1 (en) | Herbal extract, pharmaceutical composition including the same and health functional food including the same | |
| CN110772564A (en) | Traditional Chinese medicine extract composition with depression mood regulating effect, preparation method thereof and traditional Chinese medicine preparation | |
| WO2016124080A1 (en) | Use of 20(r)-ginsenoside rg3 in preparation of drug for preventing or/and treating obesity and drug | |
| CN112274607A (en) | Pharmaceutical composition for treating polyp | |
| CN115607638A (en) | Traditional Chinese medicine composition for infantile indigestion with food retention and preparation method thereof | |
| CN113952377A (en) | Traditional Chinese medicine composition for treating qi deficiency syndrome and preparation method and application thereof | |
| CN105770920B (en) | A kind of pharmaceutical preparation and its application for stomach and intestine color ultrasound assistant | |
| CN111228389A (en) | Application of aloe catharsis capsule in preparing medicine for preventing and treating abdominal distension | |
| CN111297974A (en) | Application of traditional Chinese medicine composition in preparation of medicine for treating food stagnation | |
| CN103071010B (en) | Traditional Chinese medicine preparation for treating disorders of gastrointestinal motility | |
| CN110051785A (en) | A kind of composition and its preparation and preparation method for protecting gastric mucosa | |
| CN100396299C (en) | Medication for treating astriction, and preparation method | |
| CN106620367A (en) | Traditional Chinese medicine sustained-release capsule for treating cystolith and preparation method thereof | |
| CN116370574B (en) | Traditional Chinese medicine composition for preventing and treating gosling gout and preparation method thereof | |
| CN101361806B (en) | Traditional Chinese medicine formulation for treating gastrosis and preparation method thereof | |
| CN109200138B (en) | A pharmaceutical composition for treating hemorrhoid | |
| CN101125194A (en) | Medicine composition for curing infantile diarrhea | |
| CN105267929A (en) | Micro-powder capsule for treating peptic ulcer | |
| CN115624536A (en) | Medicinal composition for reducing blood pressure, preparation containing same and application |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |